Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

F0030000

Felodipin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

4-(2,3-Dichlorphenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridincarbonsäure-ethyl-methylester, Plendil

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C18H19NO4Cl2
CAS-Nummer:
72509-76-3
Molekulargewicht:
384.25
MDL-Nummer:
MFCD00868316
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329799620
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

felodipine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(Cl)c2Cl)C(=O)OC

InChI

1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

InChIKey

RZTAMFZIAATZDJ-UHFFFAOYSA-N

Angaben zum Gen

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Felodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

L-type calcium channel blocker

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2 Inhalation

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

W C Little et al.
Cardiovascular drugs and therapy, 9(5), 657-663 (1995-10-01)
Calcium entry through L-type calcium channels is essential for contraction of both arterial smooth muscle and the myocardium, and is important in cardiac conduction. First-generation calcium entry blockers lack or have a modest degree of vascular selectivity and inhibit cardiac
P A Todd et al.
Drugs, 44(2), 251-277 (1992-08-01)
Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily. More recently considerable experience has been gained with an extended release (ER) formulation which has the convenience of once daily administration. Felodipine ER
H Purcell et al.
The British journal of clinical practice, 48(6), 311-316 (1994-11-01)
Hypertension is accompanied by a series of structural adaptations and pathological alterations in the heart and vessels. These include hypertrophy of the left ventricle and walls of resistance vessels, degeneration of elastic components in the walls of large arteries, atherosclerosis
T O Morgan
Journal of cardiovascular pharmacology, 15 Suppl 4, S76-S84 (1990-01-01)
Felodipine is a dihydropyridine that blocks the slow entry channel for calcium. It is highly vascular selective and reduces blood pressure (BP) by dilatation of peripheral arterioles. It reduces BP in mild, moderate, and severe hypertension, and the fall in
Sayantan Chattoraj et al.
Journal of pharmaceutical sciences, 103(12), 3950-3957 (2014-10-30)
The nonisothermal crystallization kinetics of amorphous materials is routinely analyzed by statistically fitting the crystallization data to kinetic models. In this work, we systematically evaluate how the model-dependent crystallization kinetics is impacted by variations in the heating rate and the
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.